Chemed and Zevia Face Market Sell-Off After Q4 Revenue Misses
Chemed Corporation and Zevia PBC both reported fourth-quarter 2025 revenue figures that fell short of Wall Street expectations, triggering significant stock price declines. Chemed, a major player in the hospice care sector through VITAS, saw its shares plummet 14.7% as investors reacted to the top-line disappointment.
Beat this week
Last 7 days · Market Trends
Impact 6.0/10 (+0.3 vs prior). Counts are stories in our record, not a market forecast.
Open the change reportCoverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 50 percentage points.
This story sits in Market Trends — the counts compare this beat's last 7 days with the previous 7 in our verified record, not a market forecast.
Figures are computed live from our source-verified story record (as of ) The volume change compares this window with the prior 7 days in the same record. — see our methodology for how impact and sentiment are derived.
Healthcare briefing
Key takeaways
- Chemed Corporation and Zevia PBC both reported fourth-quarter 2025 revenue figures that fell short of Wall Street expectations, triggering significant stock price declines.
- Chemed, a major player in the hospice care sector through VITAS, saw its shares plummet 14.7% as investors reacted to the top-line disappointment.
- markets.financialcontent.com
In this briefing
Mentioned
Key Intelligence
Key Facts
- 1Chemed Corporation (CHE) reported Q4 2025 sales below analyst estimates, leading to a 14.7% stock price drop.
- 2Zevia PBC (ZVIA) missed Q4 2025 revenue projections, resulting in a significant decline in share value.
- 3Chemed is the parent company of VITAS Healthcare, the largest hospice provider in the United States.
- 4The earnings misses occurred during the final quarter of the 2025 calendar year.
- 5Market reaction suggests heightened investor sensitivity to top-line growth in the healthcare and wellness sectors.
| Company | |||
|---|---|---|---|
| Chemed Corp | CHE | Healthcare Services (Hospice) | -14.7% Stock Drop |
| Zevia PBC | ZVIA | Health & Wellness (Beverages) | Stock Price Decline |
Analysis
The fourth-quarter earnings season for 2025 has delivered a stark reminder of the market's intolerance for revenue misses, particularly in the healthcare services and health-conscious consumer sectors. Chemed Corporation (CHE) and Zevia PBC (ZVIA) both reported financial results for the period ending December 31, 2025, that failed to meet analyst projections. The immediate market reaction was swift and punitive, with Chemed experiencing a double-digit percentage drop in its share price, signaling deeper investor concerns regarding the growth trajectory of healthcare service providers in the current economic climate.
Chemed's performance is a critical bellwether for the healthcare industry due to its ownership of VITAS Healthcare, the nation's largest provider of end-of-life care. A revenue miss in this segment is rarely an isolated event; it often reflects broader systemic challenges such as fluctuating patient census numbers, labor shortages among specialized nursing staff, or shifts in Medicare reimbursement dynamics. For Chemed, the 14.7% stock decline suggests that the revenue shortfall was not merely a rounding error but perhaps an indication of slowing volume growth or increased pressure on net revenue per patient day. In the hospice sector, where margins are tightly managed against federal caps and regulatory oversight, even a slight top-line miss can lead to significant downward revisions in valuation multiples.
Chemed Corporation (CHE) and Zevia PBC (ZVIA) both reported financial results for the period ending December 31, 2025, that failed to meet analyst projections.
Simultaneously, Zevia PBC, a leader in the zero-sugar, naturally sweetened beverage market, reported its own set of disappointing figures. While Zevia operates at the intersection of consumer goods and wellness, its performance is often viewed as a proxy for the 'better-for-you' category's resilience. The miss in Q4 2025 suggests that the premium health-conscious consumer segment may be feeling the pinch of sustained inflation or shifting retail preferences. For a company that has positioned itself as a disruptor to traditional soda giants, a revenue miss at this stage of its growth cycle raises questions about its ability to maintain market share gains against increasingly aggressive competition from established players launching their own health-focused product lines.
What to Watch
From an analyst perspective, these dual misses highlight a trend of 'top-line fragility' in the health and wellness space. Investors are no longer satisfied with bottom-line beats driven solely by cost-cutting; they are demanding robust organic revenue growth as proof of long-term viability. For Chemed, the focus in the coming quarters will be on VITAS's ability to stabilize its clinician workforce and improve patient admissions. For Zevia, the challenge lies in expanding distribution channels and maintaining brand loyalty in a crowded marketplace. The sharp sell-off in both stocks underscores the high stakes of the Q4 reporting period, where any deviation from the growth narrative is met with immediate capital flight.
Looking forward, the healthcare services sector remains under a microscope. As reimbursement models continue to evolve toward value-based care, providers like VITAS must demonstrate that they can manage costs without sacrificing the volume growth that drives revenue. Meanwhile, the wellness consumer market is entering a phase of consolidation where only the most operationally efficient brands will thrive. The Q4 2025 results for Chemed and Zevia serve as a cautionary tale for the industry: in a high-interest-rate environment with discerning investors, there is very little room for error on the top line.
Source cluster
Primary reporting
Cite This Page
"Chemed and Zevia Face Market Sell-Off After Q4 Revenue Misses." Healthcare Intelligence Brief, February 25, 2026. https://gethealthbrief.com/story/chemed-zevia-q4-2025-earnings-miss
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |